Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

RADNOR, Pa. , April 30, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. ("Amgen") (NASDAQ: AMGN).

Kessler Topaz Meltzer & Check, LLP Reminds Amgen Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit

NEW YORK , April 29, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the "Class Period"), of the important May 12, 2023 . SO WHAT: If you purchased Amgen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important May 12 Deadline in Securities Class Action - AMGN

Amgen (AMGN) beats estimates for earnings but misses the same for sales. It raises its earnings and sales guidance for 2023.

Amgen (AMGN) Q1 Earnings Beat Estimates, 2023 View Raised

Amgen Inc. (AMGN) Q1 2023 Earnings Call Transcript.

Amgen Inc. (AMGN) Q1 2023 Earnings Call Transcript

Amgen (AMGN) came out with quarterly earnings of $3.98 per share, beating the Zacks Consensus Estimate of $3.84 per share. This compares to earnings of $4.25 per share a year ago.

Amgen (AMGN) Q1 Earnings Beat Estimates

THOUSAND OAKS, Calif. , April 27, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2023.

AMGEN REPORTS FIRST QUARTER FINANCIAL RESULTS

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. (“Amgen”) (NASDAQ: AMGN). The action charges Amgen with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Amg.

Amgen Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Amgen Inc. of Deadline in Securities Fraud Class Action Lawsuit

Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Can Amgen (AMGN) Keep the Earnings Streak Alive in Q1?

ACADIA Pharma

Regeneron Pharmaceuticals

Sanofi

We look at a few pharma/biotech companies, SNY, AMGN, REGN, ACAD, which are poised to beat on earnings in the first quarter.

4 Pharma, Biotech Stocks Poised to Beat Q1 Earnings Estimates

NEW YORK , April 22, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the "Class Period"), of the important May 12, 2023 . SO WHAT: If you purchased Amgen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A RESPECTED AND LEADING FIRM, Encourages Amgen Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AMGN

THOUSAND OAKS, Calif. , April 21, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter financial results on Thursday, April 27, 2023, after the close of the U.S. financial markets.

AMGEN ANNOUNCES WEBCAST OF 2023 FIRST QUARTER FINANCIAL RESULTS

RADNOR, Pa. , April 21, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. ("Amgen") (NASDAQ: AMGN).

Kessler Topaz Meltzer & Check, LLP Reminds Amgen Inc. Investors of Important Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm

Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Amgen (AMGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

The Appeal Court's decision upholding the patents for Amgen's (AMGN) blockbuster psoriasis drug Otezla will prevent drug-makers from selling a generic version till February 2028.

Amgen (AMGN) Wins Patent Appeal for Blockbuster Psoriasis Drug

Appeals Court Affirms Validity of Patent Expiring in 2028 THOUSAND OAKS, Calif. , April 19, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Court of Appeals for the Federal Circuit has affirmed the judgment of the U.S. District Court for the District of New Jersey in a patent infringement lawsuit against Sandoz Inc. ("Sandoz") and Zydus Pharmaceuticals (USA), Inc. ("Zydus").

AMGEN WINS PATENT APPEAL ON OTEZLA® (APREMILAST)

Amgen has substantial risk from continued loss of exclusivity but an impressive portfolio of assets. The company continues to pay a dividend of more than 3% with modest net debt and continued strong earnings.

Amgen Has Long-Term Staying Power

Apple

Dow Inc

Whirlpool

Accenture Plc

HCA Healthcare

Nucor

Many investors have heard the phrase “cash is king” relative to the current banking crisis. But it also has significance for dividend investors.

7 Dividend Stocks to Buy That Are Backed by Strong Cash Flows

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the "Class Period"), of the important May 12, 2023.

ROSEN, A TOP RANKED FIRM, Encourages Amgen Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action - AMGN

Cardinal Health

Merck

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts - Cardinal Health (NYSE:CAH), Amgen (NASDAQ:AMGN)

Gilead Sciences

Novartis

Pfizer

Walgreens

First-quarter earnings kick off in a big way on Friday with the major banks posting their results.

Why 7 of the Highest-Yielding ‘Strong Buy' Health Care Stocks Are the Absolute Best 2023 Buys

Archer-Daniels-Midland Company

Aflac

Allegion

Broadcom

Becton, Dickinson and Co.

Dover

Con Ed

Embecta Corp

Emerson Electric

W.W. Grainger

Johnson & Johnson

Kraft Heinz

Kontoor Brands Inc

LyondellBasell Industries

McDonald's

Microsoft

PepsiCo

Southern Company

Southern Co 5.25 % Notes 2017-01.12.77 Global Series 2017B

T. Rowe Price Group

The system is clearly broken, and has been for a while; however, I could find comfort in one thing, my dividends. Four figures in a month is a win in my book. Earning $1,893.81 represents 12.6% year over year increase in passive income.

DivHut Portfolio Update: March 2023

NEW YORK--(BUSINESS WIRE)---- $AMGN #AMGN--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Amgen Inc. (NASDAQ: AMGN) between July 29, 2020 and April 27, 2022, both dates inclusive (the “Class Period”), of the important May 12, 2023. SO WHAT: If you purchased Amgen securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

AMGN SHAREHOLDER ALERT: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Amgen Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AMGN

RADNOR, Pa. , April 11, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Amgen Inc. ("Amgen") (NASDAQ: AMGN).

Amgen Class Action Lawsuit Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Amgen Inc. Investors That a Securities Fraud Class Action Lawsuit Has Been Filed on Their Behalf

American Express

ConocoPhillips

Macerich

Occidental Petroleum

Simon Property Group

With the goal of generating long-term capital appreciation, the Smead Value Fund (Trades, Portfolio) is known for investing in a concentrated number of stocks that have strong competitive advantages.

Diving Into the Smead Value Fund's Top Holdings as Value Conference Approaches

CVS Health

Medical Properties Trust

CVS Health is famous for its pharmacies, but it's the non-retail aspect of its business that makes it a great dividend stock to buy now. Amgen's biotechnology operation could get a lot bigger with the proposed acquisition of Horizon Therapeutics this year.

News for Amgen Stock (AMGN)